Patents Examined by Kagnew H. Gebreyesus
  • Patent number: 11072787
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 27, 2021
    Assignee: aTyr Pharma Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Patent number: 11041181
    Abstract: The present disclosure relates to a polynucleotide having a novel promoter activity, a composition for expressing a gene comprising the polynucleotide, a microorganism comprising the gene, and a method for preparing purine nucleotides using the microorganism.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: June 22, 2021
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Min Ji Baek, Ji Hye Lee, So Jung Park, Jee Yeon Bae
  • Patent number: 11041002
    Abstract: The methods and systems disclose enzymes that function to import malonic acid or malonates into a cell. The enzymes increase the output of precursor molecules by enriching certain pathways in the cell. The precursor molecules can be converted to cannabinoids. The enzymes are a family of proteins which have a majority of common alignments.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: June 22, 2021
    Assignee: CB THERAPEUTICS, INC.
    Inventors: Erin Marie Scott, Jacob Michael Vogan
  • Patent number: 11041174
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: June 22, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: David Paschon, Lei Zhang
  • Patent number: 11034967
    Abstract: The present invention provides for novel metabolic pathways to reduce or eliminate glycerol production and increase product formation. More specifically, the invention provides for a recombinant microorganism comprising a deletion of one or more native enzymes that function to produce glycerol and/or regulate glycerol synthesis and one or more native and/or heterologous enzymes that function in one or more engineered metabolic pathways to convert a carbohydrate source, such as lignocellulose, to a product, such as ethanol, wherein the one or more native and/or heterologous enzymes is activated, upregulated, or downregulated.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 15, 2021
    Assignee: Lallemand Hungary Liquidity Management LLC
    Inventors: Aaron Argyros, William Ryan Sillers, Trisha Barrett, Nicky Caiazza, Arthur J. Shaw, IV
  • Patent number: 10988787
    Abstract: Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (BIAs). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to BIAs of the host cell. Also provided are methods of producing the BIAs of interest by culturing the host cells under culture conditions that promote expression of enzymes encoded by the heterologous coding sequences of the host cells. Aspects of the invention further include compositions, e.g., host cells, starting compounds and kits, etc., that find use in methods of the invention.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: April 27, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Christina D. Smolke, Catherine Thodey, Isis Trenchard, Stephanie Galanie
  • Patent number: 10988783
    Abstract: This document describes biochemical pathways for producing 7-aminoheptanoic acid using a ?-ketoacyl synthase or a ?-ketothiolase to form either a 5-amino-3-oxopentanoyl-[ACP] or 5-amino-3-oxopentanoyl-CoA intermediate. 7-aminoheptanoic acid can be enzymatically converted to pimelic acid, 7-hydroxyheptanoic acid, heptamethylenediamine or 1,7-heptanediol or the corresponding salts thereof. This document also describes recombinant microorganisms producing 7-aminoheptanoic acid as well as pimelic acid, 7-hydroxyheptanoic acid, heptamethylenediamine and 1,7-heptanediol or the corresponding salts thereof.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: April 27, 2021
    Assignee: INV NYLON CHEMICALS AMERICAS, LLC
    Inventors: Alex Van Eck Conradie, Adriana Leonora Botes, Jonathan Kennedy, Nadia Fatma Kadi
  • Patent number: 10988773
    Abstract: Described herein are engineered microalgae that exhibit enhanced lipid production during exponential growth. Such engineered microalgae are useful, for example, for the production of biofuels.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: April 27, 2021
    Assignee: J. Craig Venter Institute
    Inventors: Andrew Allen, Christopher L. Dupont
  • Patent number: 10980817
    Abstract: Disclosed is a genetically modified host organism for expressing an anthracyclinone analogue. The genetically modified host organism comprises (i) synthetic nucleic acids; (ii) a biosynthetic pathway encoded by the synthetic nucleic acids, the (ii) biosynthetic pathway comprising a ketosynthase alpha, a ketosynthase beta/chain-length factor, an acyl carrier protein, a 3-oxoacyl-ACP synthase, a propionyl-CoA acyltransferase, a 9-ketoreductase, an aromatase/cyclase, and a second/third-ring cyclase; and (iii) a promoter positioned upstream of and operatively associated with the (ii) biosynthetic pathway. A method and corresponding synthetic nucleic acids are also disclosed.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: April 20, 2021
    Inventor: Stephen Eric Nybo
  • Patent number: 10982273
    Abstract: The invention is directed to methods and kits for performing an RNase H2-mediated cleavage reaction on a sample in an emulsion.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: April 20, 2021
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Joseph Dobosy, Sarah Jacobi, Richard Owczarzy, Mark Behlke, Jessica Lister
  • Patent number: 10975367
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: April 13, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 10954538
    Abstract: The present invention relates to processes for the preparation of sclareolide and related compounds by the biocatalytic cyclization of polyunsaturated carboxylic acid compounds, in particular of homofarnesylic acid and related compounds; and to a process for the preparation of ambroxide via the biocatalytic cyclization of homofarnesylic acid to sclareolide.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: March 23, 2021
    Inventors: Michael Breuer, Wolfgang Siegel, Stefan Ruedenauer, Ralf Pelzer
  • Patent number: 10947569
    Abstract: Described are recombinant microorganisms characterized by having phosphoketolase activity, having a diminished or inactivated Embden-Meyerhof-Parnas pathway (EMPP) by inactivation of the gene(s) encoding phosphofructokinase or by reducing phosphofructokinase activity as compared to a non-modified microorganism and having a diminished or inactivated oxidative branch of the pentose phosphate pathway (PPP) by inactivation of the gene(s) encoding glucose-6-phosphate dehydrogenase or by reducing glucose-6-phosphate dehydrogenase activity as compared to a non-modified microorganism. These microorganisms can be used for the production of useful metabolites such as acetone, isobutene or propene.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: March 16, 2021
    Assignee: Scientist of Fortune, S.A.
    Inventor: Philippe Marlière
  • Patent number: 10941214
    Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: March 9, 2021
    Assignees: aTyr Pharma, Inc., Paneu BioPharma Limited
    Inventors: Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
  • Patent number: 10941391
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: March 9, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 10934563
    Abstract: Described is a recombinant expression vector that enables a cell transformed to contain and express the vector to use levulinic acid as a carbon source, thereby converting levulnic acid into 2-butanne. Also described are genetically modified cells transformed to contain and express the vector and methods of using the cells to produce 2-butanone from a medium containing levulinic acid.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: March 2, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Brian Frederick Pfleger, Jacqueline Marie Rand, Christopher Robert Mehrer, Matthew Ryan Incha
  • Patent number: 10934537
    Abstract: The present invention relates to a nucleic acid molecule which encodes a polypeptide having cellulase activity and which is thermostable, wherein said nucleic acid molecule comprises or has a nucleotide sequence selected from: i) a nucleotide sequence which encodes an amino acid sequence as set forth in SEQ ID NO. 2 or as set forth in SEQ ID NO. 8; ii) a nucleotide sequence which encodes an amino acid sequence having at least 80% sequence identity to the amino acid sequence of (i); iii) a nucleotide sequence which encodes a part of the amino acid sequence of (i); iv) a nucleotide sequence which encodes a part of the amino acid sequence of (ii) wherein said part has at least 90% identity to an amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18 or SEQ ID NO. 20; v) a nucleotide sequence as set forth in SEQ ID NO. 1 or as set forth in SEQ ID NO.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: March 2, 2021
    Assignee: SINTEFF TTO AS
    Inventors: Alexander Wentzel, Anna Sofia Lewin, Mark Liles, Jinglie Zhou
  • Patent number: 10920256
    Abstract: The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: February 16, 2021
    Assignees: Vestlandets Innovasjonsseiskap AS, NEWSOUTH INNOVATIONS PTY LIMITED
    Inventors: Ralf Kellmann, Brett Neilan
  • Patent number: 10919963
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: February 16, 2021
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10920211
    Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: February 16, 2021
    Assignee: Research Development Foundation
    Inventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung